Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program
Objective: To describe an injectable extended-release antipsychotic pharmacotherapeutic follow-up program and to assess adherence among patients included in the program. Method: A coordinated program is described involving hospital and primary care pharmacy, which included electronic prescriptio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-11-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11188.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846093807095906304 |
|---|---|
| author | Carmen Gallastegui Hadriana Fernández-Vega Guadalupe Piñeiro Isabel Rey-Gómez-Serranillos José M. Olivares Elena de las Heras-Liñero |
| author_facet | Carmen Gallastegui Hadriana Fernández-Vega Guadalupe Piñeiro Isabel Rey-Gómez-Serranillos José M. Olivares Elena de las Heras-Liñero |
| author_sort | Carmen Gallastegui |
| collection | DOAJ |
| description | Objective: To describe an injectable extended-release antipsychotic pharmacotherapeutic follow-up program and to assess adherence among patients included in the program.
Method: A coordinated program is described involving hospital and primary care pharmacy, which included electronic prescription, reviewing, and dispensing of injectable antipsychotic agents in mental health and primary health care centers. Adherence to treatment was assessed in a 1-month prospective observational cross-sectional study which included all patients under treatment with injectable extended- release antipsychotics in a health area of more than 500,000 inhabitants. The variables collected were: medication administered, frequency of administration, administration center, and whether or not the patient attended the center. Patients were considered to have adhered to treatment if they had attended their appointments within a margin of ± 7 days.
Results: A total of 919 patients and 1,073 appointments were included. Eleven mental health units and 40 primary health care centers participated in data collection. In 95.7 % (1,027) of cases, the patients attended the appointment. No differences were found in adherence between drugs or administration frequency. However, differences were found between mental health units and primary health care centers. Patient adherence was slightly higher in mental health units (97.6% vs 91.1%; P < 0.001).
Conclusions: The high adherence rate shows that the described followup program is effective. Further long-term studies are needed to confirm this trend. |
| format | Article |
| id | doaj-art-cc0a4517def742859a03ebe681b06088 |
| institution | Kabale University |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2019-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-cc0a4517def742859a03ebe681b060882025-01-02T16:24:36ZengElsevierFarmacia Hospitalaria1130-63432171-86952019-11-0143617718110.7399/fh.11188Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up programCarmen Gallastegui0Hadriana Fernández-Vega1Guadalupe Piñeiro2Isabel Rey-Gómez-Serranillos3José M. Olivares4Elena de las Heras-Liñero5Servicio de Farmacia. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainServicio de Farmacia. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainServicio de Farmacia. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainFarmacia de Atención Primaria. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainServicio de Psiquiatría y Área de Investigación en Neurociencia Traslacional. Instituto de Investigación Biomédica Galicia Sur (IIBGS). CIBERSAM. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainInvestigación en Neurociencia Traslacional. Instituto de Investigación Biomédica Galicia Sur (IIBGS). CIBERSAM. Xerencia de Xestión Integrada de Vigo (Servicio Gallego de Salud [SERGAS]), Vigo. SpainObjective: To describe an injectable extended-release antipsychotic pharmacotherapeutic follow-up program and to assess adherence among patients included in the program. Method: A coordinated program is described involving hospital and primary care pharmacy, which included electronic prescription, reviewing, and dispensing of injectable antipsychotic agents in mental health and primary health care centers. Adherence to treatment was assessed in a 1-month prospective observational cross-sectional study which included all patients under treatment with injectable extended- release antipsychotics in a health area of more than 500,000 inhabitants. The variables collected were: medication administered, frequency of administration, administration center, and whether or not the patient attended the center. Patients were considered to have adhered to treatment if they had attended their appointments within a margin of ± 7 days. Results: A total of 919 patients and 1,073 appointments were included. Eleven mental health units and 40 primary health care centers participated in data collection. In 95.7 % (1,027) of cases, the patients attended the appointment. No differences were found in adherence between drugs or administration frequency. However, differences were found between mental health units and primary health care centers. Patient adherence was slightly higher in mental health units (97.6% vs 91.1%; P < 0.001). Conclusions: The high adherence rate shows that the described followup program is effective. Further long-term studies are needed to confirm this trend.http://www.aulamedica.es/fh/pdf/11188.pdfadherencemedicationantipsychotic agentsschizophrenia |
| spellingShingle | Carmen Gallastegui Hadriana Fernández-Vega Guadalupe Piñeiro Isabel Rey-Gómez-Serranillos José M. Olivares Elena de las Heras-Liñero Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program Farmacia Hospitalaria adherence medication antipsychotic agents schizophrenia |
| title | Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program |
| title_full | Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program |
| title_fullStr | Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program |
| title_full_unstemmed | Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program |
| title_short | Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program |
| title_sort | assessment of adherence to treatment with injectable extended release antipsychotics within a pharmacotherapeutic follow up program |
| topic | adherence medication antipsychotic agents schizophrenia |
| url | http://www.aulamedica.es/fh/pdf/11188.pdf |
| work_keys_str_mv | AT carmengallastegui assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram AT hadrianafernandezvega assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram AT guadalupepineiro assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram AT isabelreygomezserranillos assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram AT josemolivares assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram AT elenadelasheraslinero assessmentofadherencetotreatmentwithinjectableextendedreleaseantipsychoticswithinapharmacotherapeuticfollowupprogram |